AbbVievsEdgewise Therapeutics

ABBV and EWTX stock compared: price, dividend, valuation and results, from SEC filings.

EWTX

Edgewise Therapeutics, Inc.

$42.04

Value $4.5B

-3.75%
EWTX's page

AbbVie (ABBV) has a market value of $518B and Edgewise Therapeutics (EWTX) $4.5B. Over the last year, with dividends, ABBV moved +29.8% and EWTX +84.8%. The P/E is 50.3 for ABBV and 4.5 for EWTX. Dividend yield: ABBV 2.36%, EWTX none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$518B

    EWTX$4.5B

    ABBV is 115 times EWTX

  • Revenue, 12 months

    ABBV$66.0B

    EWTX–

  • Net income, 12 months

    ABBV$10.3B

    EWTX$1.0B

    ABBV is 10 times EWTX

  • Operating margin

    ABBV32.2%

    EWTX–

  • ROIC

    ABBV25.7%

    EWTX-29.0%

    54.6 points apart

  • P/E

    ABBV50.3

    EWTX4.5

    ABBV is 11 times EWTX

  • Dividend yield

    ABBV2.4%

    EWTX0.0%

    2.4 points apart

  • 5-year return

    ABBV+200.7%

    EWTX+107.2%

    93.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+200.7%

EWTX+107.2%

10020030020222023202420252026
Returns by period
PeriodABBVWith dividendsEWTXWith dividends
1 year since November 14, 2025+29.8%Price +26.0%+84.8%Price +84.8%
3 years since November 17, 2023+134.1%+32.8% a yearPrice +111.7%+557.9%+87.4% a yearPrice +557.9%
5 years since November 16, 2021+200.7%+24.6% a yearPrice +151.5%+107.2%+15.7% a yearPrice +107.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieEWTXEdgewise Therapeutics

Valuation

ABBVEWTX
Valuation
Price$292.82$42.04
Market value$518B$4.5B
Enterprise value (EV)$588B$3.3B
P/E50.34.5
P/E, 5-year median57.0–
P/B–2.8
EV/EBIT27.7–
Free cash flow yield3.6%–

Results and growth

ABBVEWTX
Results and growth
Revenue, 12 months$66.0B–
Net income, 12 months$10.3B$1.0B
Free cash flow, 12 months$18.9B-$202M
Earnings per share, 12 months$5.81$9.41
Revenue growth, year on year8.6%–
Revenue growth a year, past+5.9%over 5 years–
EPS growth a year, past-2.8%over 5 years–

Margins and returns on capital

ABBVEWTX
Margins and returns on capital
Gross margin73.7%–
Operating margin32.2%–
Net margin15.7%–
ROIC25.7%-29.0%
ROE–138.1%

Balance sheet

ABBVEWTX
Balance sheet
Cash$10.8B$1.2B
Total debt$80.9B$3.4M
Net debt / EBITDA3.2–
Interest cover7.1×–

Dividends and buybacks

ABBVEWTX
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%–
Shareholder yield2.6%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or EWTX

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Edgewise Therapeutics?

By market value, AbbVie ($518B) is about 114.8 times Edgewise Therapeutics ($4.5B), at today's prices.

How did ABBV and EWTX stock do over the last 5 years?

Since November 16, 2021, ABBV's price moved +151.5% and EWTX's +107.2%. With dividends: ABBV +200.7% (+24.6% a year), EWTX +107.2% (+15.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or EWTX?

The dividend yield at today's price is 2.36% for AbbVie and none for Edgewise Therapeutics. Over the last twelve months they paid $6.92 and – per share.

What is the P/E of ABBV and EWTX?

At today's price, the P/E is 50.3 for ABBV and 4.5 for EWTX. It is the share price over the last twelve months' earnings per share.

Which is the better investment, AbbVie or Edgewise Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.